Researchers among team testing new COVID-19 treatments miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19
Second monoclonal antibody from Vir-GSK collaboration to be investigated as a potential COVID-19 treatment
Preclinical data suggest VIR-7832 has two distinguishing properties: enhanced ability to clear infected cells and potential to enhance virus-specific T cell function, which could help treat and/or prevent COVID-19 infection
Trial targeted to begin in 1Q:2021 at multiple sites across the UK
SAN FRANCISCO and LONDON, Jan. 12, 2021 (GLOBE NEWSWIRE) Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced an agreement with the U.K.-based AGILE initiative to evaluate VIR-7832 in patients with mild to moderate COVID-19 in a Phase 1b/2a clinical trial. VIR-7832 is a neutralizing COVID-19 antibody that preclinical data suggests has two distinguishing properties: an enhanced ability to clear infected cells and the potential to enh
Vir, GSK In Deal With NHS-Supported AGILE To Evaluate VIR-7832 In Early Treatment Of COVID-19
The trial is due to begin in the first quarter of 2021.
VIR-7832 is a neutralizing COVID-19 antibody that preclinical data suggests has two distinguishing properties. These are an enhanced ability to clear infected cells and the potential to enhance virus-specific T-cell function, which could help treat and/or prevent COVID-19 infection.
The AGILE trial platform will be the first to test VIR-7832 in humans. According to the companies, the AGILE trial platform uses adaptable protocols and statistical models to enable the evaluation of candidate medicines for COVID-19 treatment.